The Exact Sciences and Genomic Health teams built two of the strongest and fastest growing brands in the industry, Cologuard and Oncotype DX. The Precision Oncology unit is responsible for the Oncotype DX portfolio of products and the recently acquired Paradigm therapy selection test. Our flagship Precision Oncology test, the Oncotype DX Breast Recurrence Score, is an innovative breast cancer test that examines the activity of 21 genes in a patient’s breast tumor tissue to guide individualized treatment based on a patient’s personal biology and disease. There are five tests within the Oncotype DX portfolio, and we have approximately 100 oncology and 50 urology sales representatives in the U.S. supporting adoption of these products.
Exact Sciences has the foundation needed to provide more precise, smarter answers to patients across all stages of cancer. In early 2020, we completed the acquisition of Paradigm, a company specialized in late-stage cancer therapy selection, which added a high-quality team and important new diagnostic test to our Precision Oncology business. With a design that requires less sample input and lab processing time than other therapy selection tests, the Paradigm PCDx test can provide life-changing answers to more patients, more quickly.
When Lloyd, a financial executive, was diagnosed with early-stage prostate cancer in his mid-fifties, he was inclined to do whatever was recommended to treat his cancer. After further research, however, he learned that most early-stage disease is not aggressive and may not need immediate treatment.
“Like many men, my first reaction to my diagnosis was fear. I was ready for radiation or surgical treatment, but the likely side effects of treatment – sexual and urinary dysfunction – led my wife, Joan, and me to seek more information.”
Lloyd began his search for more information about his treatment options. He asked for a second opinion, and the urologist he spoke with mentioned that the Oncotype DX Genomic Prostate Score (GPS) test could help him better understand the biological behavior of his cancer. When Lloyd received a low Oncotype DX GPS result, he decided not to undergo immediate aggressive treatment. “Genomic testing determined that my early-stage cancer was not aggressive, meaning I could choose active surveillance instead of invasive treatment,” said Lloyd. His active surveillance treatment plan consisted of regular check-ups and testing to monitor and ensure his cancer was not progressing.
Several years later, as part of Lloyd’s regular testing schedule, his PSA and a biopsy indicated that he needed surgery. “I’m very happy I chose the treatment path I did, and that I was able to delay surgery for almost 6 years. I put my trust in the Oncotype test and the science behind it, and it gave me and my doctors a clearer understanding of what the cancer was doing.”
This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the"safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect,""may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this report regarding our strategies, prospects, expectations, goals, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected growth opportunities and market share, future operating results, anticipated results of our sales, marketing and patient adherence efforts, expectations concerning payer reimbursement, and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.